Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Darrell J White, MD, Hannah Cherniawsky, BSc,MD, Tony Reiman, MD, Julie Stakiw, MD, Martha L Louzada, MDMSc, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 3173.

https://doi.org/10.1182/blood-2019-125810

Published: 2019

Journal Articles

Long Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Real Life Experience

Concetta Conticello, Marina Parisi, MD, Salvatore Leotta, Nunziatina Laura Parrinello, Enrica Martino, Valeria Calafiore, Maria Cristina Pirosa, Urosh Markovic, Alessandra Romano, MD PhD, Francesco Di Raimondo, MD

Blood (2018) 132 (Supplement 1): 5669.

https://doi.org/10.1182/blood-2018-99-120105

Published: 2018

Journal Articles

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Richard Greil, MD, Graeme Fraser, Brian Leber, MD, Reinhard Marks, Giulia Quaresmini, Jan Moritz Middeke, Gianpietro Semenzato, William Schary, Michelle Boyer, Madlaina Breuleux, PhD DAS, Noelle Crompton, Kathryn Humphrey, Paula Marlton

Blood (2018) 132 (Supplement 1): 5548.

https://doi.org/10.1182/blood-2018-99-118148

Published: 2018

Journal Articles

Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics

Janet M. Leeds, PhD, Alice Ke, Karen Rowland Yeo, John T Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 3663.

https://doi.org/10.1182/blood.V130.Suppl_1.3663.3663

Published: 2017

Journal Articles

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Benjamin Diamond, MD, David S Jayabalan, MSc, Roger Pearse, MD PhD, Art Perry, Karen Pekle, Ruben Niesvizky, MD, Adriana C. Rossi, MDMSc

Blood (2017) 130 (Supplement 1): 3102.

https://doi.org/10.1182/blood.V130.Suppl_1.3102.3102

Published: 2017

Journal Articles

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

James R Berenson, MD, Alexa Cohen, Tanya M. Spektor, PhD, Ashkan Lashkari, MD, Roy Mackintosh, MD, Alberto Bessudo, MD, Haresh Jhangiani, Nashat Gabrail, MD, Ibrahim Nakhoul, MD, Samir Kubba, MD, Jeffrey D. Neidhart, MD BS, Maluso Tina, Regina Swift, Robert Vescio, MD

Blood (2017) 130 (Supplement 1): 3106.

https://doi.org/10.1182/blood.V130.Suppl_1.3106.3106

Published: 2017

Journal Articles

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

Henrik Gregersen, MD, Niels Abildgaard, MD, Trung Hieu Do, MD, Ida Bruun Kristensen, MD, Ulf Christian Frølund, MD, Niels Frost Andersen, MD, Lene Kongsgaard Nielsen, MD, Christen Lykkegaard Andersen, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD

Blood (2017) 130 (Supplement 1): 3129.

https://doi.org/10.1182/blood.V130.Suppl_1.3129.3129

Published: 2017

Journal Articles

Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs)

Yu-Ting Chang, MS, Daniela Hernandez, MD, Gabriel Ghiaur, MD PhD, Mark J. Levis, MD, Richard J. Jones, MD

Blood (2017) 130 (Supplement 1): 2519.

https://doi.org/10.1182/blood.V130.Suppl_1.2519.2519

Published: 2017

Journal Articles

Macrolide Antibiotics By Modulating the Autophagic Flux Exert an Antileukemic Effect through the Involvement of hERG1 Potassium Channel

Serena Pillozzi, Massimo D'Amico, Giulia Petroni, Marinella Veltroni, MD, Claudio Favre, MD, Andrea Becchetti, Giuseppe Basso, Annarosa Arcangeli, MD PhD

Blood (2016) 128 (22): 3953.

https://doi.org/10.1182/blood.V128.22.3953.3953

Published: 2016

Journal Articles

Clarithromycin Interacts with Lenalidomide in the Combination Regimen Bird and Overcomes Drug Resistance in Multiple Myeloma

Fengyan Jin, MD PhD, Shuang Li, MD, Lijuan Chen, PhD, Chuan Wu, MD, Wei Li, MD, Jian Hou, MD, Yun Dai, MD PhD

Blood (2016) 128 (22): 2125.

https://doi.org/10.1182/blood.V128.22.2125.2125

Published: 2016

Journal Articles

The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone

Aimaz Afrough, MD, Amy Sidorski, CRNP, Roberto Salvatori, MD, Ivan Borrello, MD

Blood (2016) 128 (22): 5640.

https://doi.org/10.1182/blood.V128.22.5640.5640

Published: 2016

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Exerts Dose-Dependent Cytostatic and Cytocidal Effects on Multiple Myeloma Cells Via Autophagy

Noriyoshi Iriyama, MD PhD, Hirotsugu Hino, Shota Moriya, Masaki Hiramoto, Yoshihiro Hatta, MD PhD, Masami Takei, MD PhD

Blood (2016) 128 (22): 4478.

https://doi.org/10.1182/blood.V128.22.4478.4478

Published: 2016

Journal Articles

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Peter A. Forsberg, MD, Adriana C Rossi, MD, MSc, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, John N. Allan, MD, Ruben Niesvizky, MD, Tomer Mark, MD MSc

Blood (2016) 128 (22): 4518.

https://doi.org/10.1182/blood.V128.22.4518.4518

Published: 2016

Journal Articles

Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor

Suliman Al-Fayoumi, Mary S. Campbell, Sherri Amberg, Huafeng Zhou, Lindsey Millard, James P. Dean

Blood (2015) 126 (23): 5178.

https://doi.org/10.1182/blood.V126.23.5178.5178

Published: 2015

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice

Heidi D. Finnes, PharmD, Kari G. Chaffee, MS, Timothy G. Call, MD, Wei Ding, MD PhD, Deborah A. Bowen, APRN, CNP, Michael Conte, PA-C, Kristen B. McCullough, PharmD, Julianna A. Merten, PharmD, Gabriel T. Bartoo, PharmD, Matthew D. Smith, PharmD, Susan M. Schwager, Susan L. Slager, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD

Blood (2015) 126 (23): 717.

https://doi.org/10.1182/blood.V126.23.717.717

Published: 2015

Journal Articles

Hemophagocytic Lymphohistiocytosis Associated with NK Cell Dysfunction and Disseminated Herpesvirus Infection in GATA2 Deficiency/Monomac Syndrome

Michael A. Spinner, MD, Camila Odio, B.S., Katherine R. Calvo, MD, PhD, Amy P Hsu, B.A., Christa S. Zerbe, MD, Jennifer Cuellar-Rodriguez, MD, Jennifer P. Ker, MD, Charles J. Stoudenmire, MD, Oluwole Fadare, MD, Arunima Ghosh, MD,PhD, Emily M. Mace, PhD, Jordan S. Orange, MD, PhD, Dennis D. Hickstein, MD, Steven M. Holland, MD

Blood (2014) 124 (21): 4978.

https://doi.org/10.1182/blood.V124.21.4978.4978

Published: 2014

Journal Articles

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Adriana C Rossi, MD, Ekta Aneja, MBBS, Angelique Boyer, David Jayabalan, BSMS, MSc, Tomer M Mark, MD MSc, Roger Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2014) 124 (21): 4754.

https://doi.org/10.1182/blood.V124.21.4754.4754

Published: 2014

NARROW

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Long Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Real Life Experience

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics

Carfilzomib Is Safe and Effective in Newly Diagnosed Patients with Multiple Myeloma with Renal Involvement

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

Bone Marrow Stroma Protects FLT3 Acute Myeloid Leukemia (AML) through CYP3A4-Mediated Drug Metabolization of FLT3 Tyrosine Kinase Inhibitors (TKIs)

Macrolide Antibiotics By Modulating the Autophagic Flux Exert an Antileukemic Effect through the Involvement of hERG1 Potassium Channel

Clarithromycin Interacts with Lenalidomide in the Combination Regimen Bird and Overcomes Drug Resistance in Multiple Myeloma

The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone

Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Exerts Dose-Dependent Cytostatic and Cytocidal Effects on Multiple Myeloma Cells Via Autophagy

Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM)

Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice

Hemophagocytic Lymphohistiocytosis Associated with NK Cell Dysfunction and Disseminated Herpesvirus Infection in GATA2 Deficiency/Monomac Syndrome

Effect of Renal and Hepatic Function on Pomalidomide Dose in Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only